The price-to-earnings ratio for Idexx Laboratories, Inc (NASDAQ: IDXX) is 41.82x, which is above its average ratio. Moreover, the 36-month beta value for IDXX is 1.33. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 4 as “overweight,” 3 as “hold,” and 1 as “sell.”
The public float for IDXX is 81.43M and currently, short sellers hold a 2.81% of that float. On October 31, 2024, IDXX’s average trading volume was 484.61K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
IDXX) stock’s latest price update
Idexx Laboratories, Inc (NASDAQ: IDXX)’s stock price has dropped by -6.47 in relation to previous closing price of 451.08. Nevertheless, the company has seen a loss of -6.72% in its stock price over the last five trading days. zacks.com reported 2024-10-31 that Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
IDXX’s Market Performance
IDXX’s stock has fallen by -6.72% in the past week, with a monthly drop of -13.18% and a quarterly drop of -9.97%. The volatility ratio for the week is 2.01% while the volatility levels for the last 30 days are 2.12% for Idexx Laboratories, Inc. The simple moving average for the past 20 days is -8.58% for IDXX’s stock, with a -16.30% simple moving average for the past 200 days.
Analysts’ Opinion of IDXX
Many brokerage firms have already submitted their reports for IDXX stocks, with BTIG Research repeating the rating for IDXX by listing it as a “Buy.” The predicted price for IDXX in the upcoming period, according to BTIG Research is $580 based on the research report published on July 25, 2024 of the current year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see IDXX reach a price target of $525. The rating they have provided for IDXX stocks is “Neutral” according to the report published on January 30th, 2024.
Exane BNP Paribas gave a rating of “Outperform” to IDXX, setting the target price at $602 in the report published on December 07th of the previous year.
IDXX Trading at -12.23% from the 50-Day Moving Average
After a stumble in the market that brought IDXX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.68% of loss for the given period.
Volatility was left at 2.12%, however, over the last 30 days, the volatility rate increased by 2.01%, as shares sank -13.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.58% lower at present.
During the last 5 trading sessions, IDXX fell by -7.60%, which changed the moving average for the period of 200-days by -18.93% in comparison to the 20-day moving average, which settled at $461.30. In addition, Idexx Laboratories, Inc saw -23.99% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IDXX starting from SZOSTAK M ANNE, who sale 500 shares at the price of $469.37 back on Sep 06 ’24. After this action, SZOSTAK M ANNE now owns 0 shares of Idexx Laboratories, Inc, valued at $234,686 using the latest closing price.
M. Anne Szostak, the Director of Idexx Laboratories, Inc, proposed sale 500 shares at $469.78 during a trade that took place back on Sep 06 ’24, which means that M. Anne Szostak is holding shares at $234,890 based on the most recent closing price.
Stock Fundamentals for IDXX
Current profitability levels for the company are sitting at:
- 0.29 for the present operating margin
- 0.6 for the gross margin
The net margin for Idexx Laboratories, Inc stands at 0.22. The total capital return value is set at 0.47. Equity return is now at value 63.25, with 26.91 for asset returns.
Based on Idexx Laboratories, Inc (IDXX), the company’s capital structure generated 0.38 points at debt to capital in total, while cash flow to debt ratio is standing at 1.0. The debt to equity ratio resting at 0.61. The interest coverage ratio of the stock is 363.63.
Currently, EBITDA for the company is 1.1 billion with net debt to EBITDA at 0.58. When we switch over and look at the enterprise to sales, we see a ratio of 9.35. The receivables turnover for the company is 6.22for trailing twelve months and the total asset turnover is 1.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.32.
Conclusion
To wrap up, the performance of Idexx Laboratories, Inc (IDXX) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
